High-dose Zevalin with stem cell transplant may benefit NHL patients

A study showed that 83% of patients with relapsed/refractory or high-risk aggressive non-Hodgkin's lymphoma were disease-free 30 months after receiving high-dose Zevalin and undergoing a tandem stem cell transplant. The findings add to evidence that "Zevalin at higher than FDA approved doses with a stem cell rescue may provide an added clinical benefit" when combined with standard chemotherapy, a company official said.